The latest price target for Turnstone Biologics (NASDAQ:TSBX) was reported by B of A Securities on October 14, 2024. The analyst firm set a price target for $0.50 expecting TSBX to rise to within 12 months (a possible 41.40% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Turnstone Biologics (NASDAQ:TSBX) was provided by B of A Securities, and Turnstone Biologics downgraded their neutral rating.

There is no last upgrade for Turnstone Biologics

The last downgrade for Turnstone Biologics Corp happened on October 14, 2024 when B of A Securities changed their price target from $10 to $0.5 for Turnstone Biologics Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Turnstone Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Turnstone Biologics was filed on October 14, 2024 so you should expect the next rating to be made available sometime around October 14, 2025.

While ratings are subjective and will change, the latest Turnstone Biologics (TSBX) rating was a downgraded with a price target of $10.00 to $0.50. The current price Turnstone Biologics (TSBX) is trading at is $0.35, which is out of the analyst’s predicted range.